News

Combining lenalidomide with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

Michael J. Overman, MD, discusses the combination regimen of nivolumab and ipilimumab in metastatic colorectal cancer and highlights existing challenges that still need to be addressed in future research.

Daratumumab salvage therapy demonstrated a 1-year overall survival rate of 90.9% in patients with multiple myeloma who relapsed following allogeneic stem cell transplantation and also failed several posttransplant therapies, according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.

The National Community Oncology Dispensing Association has announced the addition of hematologist and medical oncologist Barry D. Brooks, MD, to its executive council in April.

A look back at all the FDA news that happened in the month of April 2019, including several new approvals, a priority review, breakthrough designation, and more.

The PDGFRα antagonist olaratumab (Lartruvo) will be withdrawn from the market for the treatment of patients with advanced soft tissue sarcoma due to disappointing findings in the phase III ANNOUNCE trial, according to Eli Lilly and Company.

Apalutamide has been submitted for FDA approval for the treatment of patients with metastatic castration-sensitive prostate cancer.

According to a single-institution retrospective study recently published in&nbsp;<em>Clinical Lymphoma, Myeloma &amp; Leukemia,&nbsp;</em>minimally toxic first-line therapies may be beneficial in early extranodal follicular lymphoma compared with observation.

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has been launched by Roche to help identify&nbsp;<em>HER2</em> amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

A new drug application seeking the approval of darolutamide as a treatment for patients with nonmetastatic castration-resistant prostate cancer has been granted a priority review designation by the FDA.

David R. Gandara, MD, discusses the treatment decisions he makes and the data that support his recommendations for treating patients with non&ndash;small cell lung cancer

Significantly higher response rates were seen in patients with&nbsp;<em>ALK</em>-positive non&ndash;small cell lung cancer who had been treated with at least 1 prior ALK tyrosine kinase inhibitor &nbsp;before receiving lorlatinib and who harbored an&nbsp;<em>ALK&nbsp;</em>resistance mutation compared with those who did not have an&nbsp;<em>ALK&nbsp;</em>mutation.

Clinical outcomes were consistent among transplant-eligible patients with mantle cell lymphoma, regardless of which chemoimmunotherapy induction treatment was administered to the patient.

Treatment with&nbsp;tagraxofusp led to a high rate of responses in patients with&nbsp;blastic plasmacytoid dendritic cell neoplasm regardless of whether patients had received prior treatment or not, findings from a nonrandomized phase II trial demonstrated.

While predictive genetic testing is useful and even crucial for many populations, new medical advances are routinely overhyped in the media and misunderstood by consumers and providers alike.

The first patient has been dosed in a phase III clinical trial investigating the addition of uproleselan (GMI-1271) to standard 7+3 chemotherapy in older patients with previously untreated acute myeloid leukemia.

Kristen Ciombor, MD, MSCI,&nbsp;discusses the promise of liquid biopsies in the rapidly evolving mCRC paradigm and the potential implications of the COLOMATE trial.

Maria E. Cabanillas, MD, discusses some of the ongoing thyroid cancer clinical trials at The University of Texas MD Anderson Cancer Center, as well as other promising research on the horizon across all subtypes of the disease.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Josephine Louella Feliciano, MD, explained the treatment considerations and decisions she makes when treating a patient with non&ndash;small cell lung cancer in the clinic and the data that support these options to a group of physicians.

New guidance has been developed for the management of adverse events observed with the use of copanlisib (Aliqopa) in patients with follicular lymphoma (FL) who are on third-line or later therapy.

During a&nbsp;<em>Targeted Oncology&nbsp;</em>live case-based peer perspectives presentation, Jonathon B. Cohen, MD, MS, explained to a group of physicians the treatment considerations and decisions he makes when seeing a patient with mantle cell lymphoma in the clinic.

A new drug application seeking the approval of&nbsp;pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor will be discussed by the&nbsp;Oncologic Drugs Advisory Committee during a meeting on May 14, 2019, the FDA has announced.

Aditya Bardia, MBBS, MPH,&nbsp;discusses the potential role of circulating tumor cells and circulating tumor DNA testing in patients with breast cancer.

David Goldenberg, MD, FACS, discusses possible risk factors associated with thyroid cancer, including a retrospective analysis that looked at the effect of radiation exposure.

In a recent retrospective analysis, investigators found that initially observing patients with mantle cell lymphoma based solely on clinical criteria was an effective management strategy that did not&nbsp;compromise patient outcomes.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, Anthony Mato, MD, MSCE, explained to a group of physicians the diagnostic workup and treatment considerations and decisions he makes when seeing a patient with chronic lymphocytic leukemia in the clinic.

A new meta-analysis has found that the combined regimen of bevacizumab (Avastin) plus erlotinib (Tarceva) is effective in treating advanced or metastatic hepatocellular carcinoma.

Pembrolizumab&nbsp;(Keytruda) has received approval from the FDA&nbsp;in combination with axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma, based on phase III&nbsp; findings from the KEYNOTE-426 trial.

The approval of the PD-L1 22C3 pharmDX assay has been expanded by the FDA to be used as a companion diagnostic for identifying more patients with stage III or metastatic&nbsp;non&ndash;small cell lung cancer who can undergo frontline treatment with pembrolizumab.

According to new findings, tumor mutational burden showed promise as a predictive biomarker for survival benefit in patients with advanced non&ndash;small cell lung cancer (NSCLC) treated with&nbsp;the PD-L1 inhibitor durvalumab (Imfinzi) as initial therapy versus chemotherapy,&nbsp;even though there was no difference seen between the 2 treatment groups in the primary analysis of the randomized trial.